SILEXION THERAPEUTICS CORP Debt and Equity Securities, Gain (Loss)
SILEXION THERAPEUTICS CORP (SLXN) reported Debt and Equity Securities, Gain (Loss) of $62.50 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-29.
Discontinued
us-gaap:DebtAndEquitySecuritiesGainLoss · last filed 2024-08-29
- 2024-06-30: Debt and Equity Securities, Gain (Loss) 6 month $62.50M.
| Period end | Debt and Equity Securities, Gain (Loss) 6 month |
|---|---|
| 2024-06-30 | $62.50M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |